Fortis Memorial Research Institute | Gurgaon, India

Research site

(Unclaimed)

Location

Sector - 44, Opposite HUDA City Centre, Gurgaon, Haryana, India

Site insights

Top conditions

Top treatments

Etrasimod

Pomalidomide

ABX464

Bortezomib

Teclistamab

Ozanimod

Dexamethasone

Ibrutinib

AG 013736

Elotuzumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 22 total trials

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) thera...

Active, not recruiting

Post-essential Thrombocythemia Myelofibrosis

Post-polycythemia Vera Myelofibrosis

Drug: Physician's Choice medications

Drug: Pacritinib

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermed...

Active, not recruiting

Myelofibrosis

Drug: Imetelstat

Drug: Best Available Therapy (BAT)

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (TRIlogy-5)

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

Enrolling

Multiple Myeloma

Drug: Teclistamab

Drug: JNJ-79635322

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) w...

Active, not recruiting

Multiple Myeloma

Drug: Elotuzumab

Drug: Bortezomib

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)

The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alter...

Active, not recruiting

Relapsed or Refractory Multiple Myeloma

Drug: Dexamethasone

Drug: Pomalidomide

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting

Crohn's Disease

Biological: JNJ-78934804

Biological: Golimumab

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elri...

Enrolling

Myelodysplastic Syndromes

Drug: Placebo

Drug: Elritercept

ABTECT - Maintenance

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once d...

Active, not recruiting

Ulcerative Colitis

Drug: ABX464

Drug: Placebo

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis (ELEVATE UC OLE)

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Active, not recruiting

Ulcerative Colitis

Drug: Etrasimod

Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

This is a Phase 3, randomized, double-blind, multicenter, comparative study evaluating cefepime-zidebactam (FEP-ZID) versus ceftazidime-avibactam (CA...

Not yet enrolling

Ventilator Associated Bacterial Pneumonia (VABP)

Hospital Acquired Bacterial Pneumonia (HABP)

Drug: Ceftazidime-avibactam with or without Colistin

Drug: Cefepime-Zidebactam

Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unab...

Enrolling

Acute Myeloid Leukemia

Drug: Azacitidine

Drug: Venetoclax